Silence Therapeutics plc SLN · NASDAQ
$19.75 -0.25% (-$0.05)
Summary
17 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Revenue fell by 68% a year over the last 3 years.
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 22% this fiscal year.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 37% a year over 5 years. Over the last 3 years it fell by 68% a year. For the next fiscal year analysts expect revenue to fall by 22%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $59.9M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. The debt score is low because the company's equity is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 1
- Sell 1
Today's price within the analysts' price targets
The average target of $57 is 189% above today's price. 60% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Research Collaboration Income 100%
By region
- GERMANY 100%
Research Collaboration Income brings in 100% of revenue.
Segments in detail